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INTRODUCTION
It is estimated that 24,000 patients are diagnosed with oral cavi-
ty squamous cell carcinoma (OCSCC) in the United States each 
year (1), and oral cavity cancer ranks among the top ten most 
prevalent malignancies affecting patients worldwide (2). Squa-
mous cell carcinoma is by far the most common histology found 
for tumors of the oral cavity. Oral subsites that may be the locus 
for primary tumors include the oral tongue, floor of mouth, ret-
romolar trigone, upper and lower gingiva, hard palate, buccal 
mucosa, and the oral lips. Advanced local disease and lymph 
node metastasis are associated with poor prognosis, which is re-
flected in the current AJCC staging system (3). Lymph node me-
tastases are present in approximately 45% of patients diagnosed 
with OCSCC (4, 5), and the presence of lymph node disease de-
creases patient survival by approximately 50% (6-8).
  The treatment of advanced-stage oral cavity carcinoma current-
ly involves a mutli-disciplinary team approach led by the head 
and neck surgeon, radiation oncologist, and medical oncologist. 
The mainstay of treatment for these patients is surgical resec-
tion, neck dissection, and postoperative radiation treatment di-
rected at the primary site of disease and the draining nodal ba-
sins in the neck. However, in 2004, two large prospective ran-
domized trials evaluating patients with advanced, resectable 
head and neck squamous cell carcinomas (HNSCC) identified 
patients with extracapsular spread of cervical lymph node dis-
ease or surgical margins positive for tumor as prognostic factors 
that increased the risk for poor outcome (9-11). The addition of 
concurrent chemotherapy to postoperative radiation treatment 
was found to improve outcomes for this high-risk patient popu-
lation. Here we provide a detailed review of the contemporary 
management for patients with advanced oral cavity cancer.
DIAGNOSIS AND STAGING
The most common risk factors for the development of oral cavi-
ty cancer are the use of tobacco and alcohol. Heavy cigarette 
use is associated with a three-fold increase in the risk of OCSCC. 
Alcohol use alone contributes only slightly to the risk of OC-
SCC development, however the combination of cigarette and 
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alcohol use appears to have a synergistic effect upon the devel-
opment of OCSCC, increasing the risk 10-15 times (12). Ciga-
rette smoking is the main form of tobacco used in the western 
world, but the use of smokeless tobacco also carries a significant, 
albeit lower risk for the development of oral cancer (13). In 
South-East Asia, South Asia, and India, the use of betel quid 
(which involves chewing all or various combinations of areca 
nut, catechu, slaked lime, and tobacco wrapped in a betel leaf) 
poses a significant risk for the development of oral cancer, con-
tributing greatly to the incidence worldwide (14). Whereas over-
whelming evidence has established a role for the human papil-
loma virus (HPV) serotypes 16 and 18 in the development of 
oropharyngeal cancer, the association of HPV with oral cancer 
is much less frequent (15, 16). 
  The accessibility and visibility of the oral cavity to the patient 
and clinician makes the diagnosis of OCSCC relatively straight 
forward. The identification of the clinical features that portend 
the presence of advanced disease and risk of poor outcome are 
more challenging and important to distinguish at the time of di-
agnosis. The AJCC staging system only partially accounts for 
factors associated with advanced disease (3). On examination, 
the location and size of the oral cavity mass is important to note. 
Ulceration is also an indication of aggressive disease, and should 
be noted. Closer inspection should determine if the mass is fixed 
to or invading the mandible, tongue mobility should be as-
sessed, and neuropathy of either the second or third division of 
the trigeminal nerve distribution should be evaluated. The latter 
finding can be an ominous sign of perineural invasion and spread 
of disease. The presence of regional nodal disease has a signifi-
cant impact on disease stage and thus prognosis (3, 6). Any pal-
pable adenopathy should be identified and assessed. The risk of 
neck disease at presentation is roughly 40-50% (4, 5), and rela-
tively small lesions of the tongue and floor of mouth, with a 
depth of invasion as low as 2-4 mm, have a 15-20% rate of oc-
cult metastasis (17, 18). 
  The presence of locally advanced disease, particularly invasion 
of the mandible, pterygoid muscles, tumor involvement of the 
deep spaces and musculature of the neck, and encasement and 
invasion of the carotid artery, must be identified during the 
workup of the patient, as all these factors impact treatment plan-
ning and prognosis. The burden of lymph node metastasis must 
also be accurately assessed. After clinical examination, imaging 
is crucial in the evaluation of patients with advanced OCSCC. 
High resolution computed tomography (CT) with intravenous 
contrast provides excellent detail of the bony, vascular, and soft 
tissue structures of the head and neck, and is the mainstay for 
preoperative evaluation. Cortical bony invasion of the mandible 
is well appreciated with this modality (19), and soft tissue extent 
of disease, including carotid artery involvement can be evaluated, 
as well (20). The accuracy of diagnosing pathologically involved 
lymph nodes based on findings such as lymph node enlargement, 
loss of the fatty hilar structure, and central necrosis can yield a 
diagnostic accuracy of roughly 80-90% (21), but the ability to 
identify extracapsular spread of disease is more limited (21, 22). 
  Other imaging modalities have been employed to evaluate 
advanced OCSCC, and can provide complimentary information 
to that gained from CT scan. Magnetic resonance imaging (MRI) 
can better delineate the extent of disease involving soft tissue 
structures, such as the deep musculature of the tongue (23) or 
perineural invasion (24), and may be better at evaluating the 
extent of marrow space involvement when there is extensive 
mandibular invasion (19). The use of ultrasound has been advo-
cated as a practical, less costly, and accurate imaging modality 
for the evaluation of the cervical lymph nodes for metastases 
(25-27), but has not gained wide use in the United States for 
this disease.
  During the past decade, fluorodeoxyglucose (
18F) positron 
emission tomography (FDG-PET) alone or combined with CT 
scan has become widely used for preoperative evaluation and 
post-treatment assessment of patients with OCSCC. The in-
creased affinity of tumor cells for glucose causes relative accu-
mulation of FDG, and PET scanning can then be used to identi-
fy and localize sites of tumor involvement. Though PET scan has 
been shown to be a powerful tool, and potentially cost-effective 
for the identification of recurrent disease (28, 29), distant metas-
tasis, and second primary disease (30), the benefit of FDG-PET 
for the identification of lymph node metastases prior to surgery 
for OCSCC remains an area of controversy. Recently, Lonneux 
et al. (31) suggested that pre-treatment FDG-PET could improve 
the accuracy of TNM staging and alter management in a signifi-
cant number of patients, however the costs and benefits of this 
application of FDG-PET is still under debate (32). 
  In addition to evaluation of the local and regional burden of 
disease in advanced OCSCC, a metastatic work-up is necessary 
prior to the formulation of a definitive treatment plan. As men-
tioned above, if pre-treatment FDG-PET is used, it can be a 
valuable tool for the identification of distant metastasis (DM), 
and if applied in patients at high-risk of DM, can be cost-effec-
tive (30). If FDG-PET is not employed, chest X-ray or chest CT 
can be used to rule out the presence of pulmonary metastases. 
Additional laboratory and imaging tests are used, including a 
liver function panel and abdominal CT if a high suspicion for 
hepatic metastases exists. An evaluation of the patients’ func-
tional status and a thorough examination of the patient and his 
or her associated co-morbidities is important to determine if in-
tensive therapy, including surgery, radiation, and systemic cyto-
toxic chemotherapy, will be tolerated. 
SURGICAL TREATMENT
Surgical management of primary site
Treatment for advanced OCSCC requires multi-modality thera-
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because high-dose radiation to the mandible can result in the 
development of osteoradionecrosis (33). During the removal of 
disease in the oral cavity, an attempt is made to achieve a 1-1.5 
cm soft tissue margin around gross tumor. When the mandible is 
involved, marginal mandibulectomy is acceptable if the outer ta-
ble of cortical bone is not directly invaded by tumor, while seg-
mental resection of the mandible is preferred if there is gross 
bone invasion (34). Removal of T1 or T2 lesions can often be 
achieved with little functional deficit and simple closure or re-
construction- examples include partial glossectomy with prima-
ry closure, or simple floor of mouth excision with split-thickness 
skin graft. 
  When local disease is advanced, a more complex resection and 
reconstruction is often required. Planning for large resections of 
the oral cavity can be challenging, and several approaches exist 
in order to achieve these procedures with the least functional 
and cosmetic deficits. Two important decisions in approaching 
the oral cavity involve the necessity to split the lower lip with 
the incision, and similarly to split the mandible to approach pos-
terior regions of the oral cavity, tongue, and extension to the 
pharynx (35, 36). The risk of poor healing after mandibulotomy, 
fistula formation, and the cosmetic result of the lip-split incision 
must be weighed against the reduced surgical access with a tran-
soral approach or visor flap, and possible functional deficits in 
chewing or swallowing associated with the lingual-release ap-
proach (37). Disease that involves the maxilla or hard palate may 
necessitate a gingival-buccal incision, or potentially a Weber-Fer-
guson facial flap for large palato-maxillary resections. 
  Achieving a surgical margin negative for tumor is of utmost 
importance. Two large multicenter, randomized-controlled trials 
have definitively confirmed positive surgical margins as a risk 
factor for poor outcome (9-11). If disease has spread to the para-
vertebral muscles, invaded the skull-base, or encased or invaded 
the carotid artery a negative surgical margin may be difficult or 
impossible to achieve. In cases where disease is unresectable, 
other modalities of treatment must be considered. The develop-
ment and improvements upon the various microvascular free-
tissue transfer options now available have greatly improved the 
cosmetic and functional outcomes for patients with large, com-
plex resections of the oral cavity. Improved reconstruction in the 
head and neck has greatly enhanced our ability to resect large 
oral cavity tumors with improved functional outcome, and these 
are summarized in a separate section below. 
Surgical management of the neck
Lymph node metastasis is common in OCSCC, occurring in 
roughly 45% of patients at presentation (4). Neck dissection, 
the en bloc resection of cervical lymph nodes, has long been ad-
vocated for the removal and control of metastatic disease in the 
cervical region (38, 39). Neck dissection can be both therapeutic 
and diagnostic. When lymphatic metastases are evident, thera-
peutic neck dissection often involves complete extirpation of the 
cervical lymphatics from all levels of the neck involved with and 
at risk of having metastases. The original description of the radi-
cal neck dissection additionally involved resection of the sterno-
cleidomastoid muscle, internal jugular vein, and accessory nerve 
(38, 40, 41), but has since been modified to preserve these struc-
tures when not directly involved with metastatic disease (42, 43). 
When extensive disease is present, and removal of the sterno-
cleidomastoid muscle is necessary, either regional or free-tissue 
transfer is often performed, such as a pectoralis major flap, in 
order to adequately cover the carotid artery and reduce the risk 
of carotid artery exposure and rupture. During the last three de-
cades, the decision to perform a modified radical versus a selec-
tive neck dissection to treat cervical metastatic disease has be-
come increasingly refined, and the specific indications for these 
procedures is still under debate. In the current strategy for oral 
cavity cancer, the literature supports that modified radical neck 
dissection, where all five levels of lymphatic tissue are removed, 
is reserved for cases where there is extensive disease, such as the 
presence of N3 disease, extensive extracapsular spread, or when 
there is identifiable disease in levels IV or V. In the era of post-
operative radiation to the neck after removal of nodal metasta-
sis, selective neck dissection has been used to treat N1 or N2 
disease and has yielded outcomes equivalent to those treated 
with modified radical neck dissection (44-46). For OCSCC, se-
lective neck dissection typically involves removal of levels I, II, 
and III. Level IV is often removed based on the surgeon’s phi-
losophy, and it is still debated when these nodes should be re-
moved or spared in this setting. 
  When patients present with oral cavity cancer and do not 
have clinical or radiologic evidence for cervical metastatic dis-
ease, a decision must be made for elective resection of the cervi-
cal lymph nodes. In these cases, neck dissection can be both 
therapeutic (i.e., the removal of unidentifiable microscopic dis-
ease), and diagnostic (i.e., if microscopic lymph node metastasis 
is identified, post-operative radiation to the cervical region may 
be added to the treatment plan). The concept of elective neck 
dissection was introduced over 50 years ago (39), and a detailed, 
critical evaluation followed, leading to the development of selec-
tive neck dissection for the management of the N0 neck (46, 47). 
It is generally accepted that lymph node groups with a 15% or 
greater risk of lymph node metastasis should be electively sam-
pled when clinical disease is not evident. For the oral tongue 
and floor of mouth, it has been shown that this threshold is 
breached for tumors with a thickness of 2-4 mm depth of inva-
sion (48), and the lymph node regions at risk for metastasis when 
disease is localized to the oral cavity are the submental, subman-
dibular, and juglular chain nodes (4, 5, 17). Thus, supraomohy-
oid neck dissection (levels Ia, Ib, II, and III) is the recommended 
procedure for elective management of the neck for OCSCC. As 
described before, elective removal of level IV is under debate. 
There is evidence that oral cavity cancer can spread to level III 
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(49), but whether this risk of “skip metastases” is high enough 
to justify risking injury to level IV structures such as the thoracic 
duct or phrenic nerve remains to be elucidated. 
  The consideration of bilateral neck dissection for advanced 
OCSCC deserves some discussion. Advanced tumors of the oral 
tongue, floor of mouth, lip, and mandible will often encroach or 
violate the midline of these regions. When this occurs, cervical 
nodes from both sides of the neck are at risk of developing met-
astatic disease (50). When disease is not clinically evident, bilat-
eral elective neck dissection is required. For more lateralized 
disease, the risk of contralateral metastasis without the presence 
of unilateral lymph node involvement is low, and the presence 
of unilateral disease after elective dissection will lead to adju-
vant radiotherapy to both sides of the neck. Thus, bilateral dis-
section in these cases is not indicated. Neck dissection to both 
sides of the neck carries some additional risk, particularly if rad-
ical neck dissection is planned. Removal of the jugular veins bi-
laterally can cause significant increase in intracranial pressure, 
which has led to the common practice of returning to the oper-
ating room at a later date (staged neck dissections) to perform 
the contralateral lymphadenectomy if it is felt the patient may 
have to undergo bilateral jugular vein sacrifice (51). Blindness is 
also a rare, but devastating complication that has been reported 
(52).
  The most recent advancement in the management of the cer-
vical lymph nodes for oral cavity cancer has been the applica-
tion of sentinel lymph node biopsy (SLNB) for patients with the 
clinically negative neck. This technique offers a potential com-
promise between “watchful waiting” and elective neck dissec-
tion for patients with primary OCSCC that carries a risk of cer-
vical metastasis. The procedure involves injection of the primary 
site with technecium-99 sulfur colloid, lymphatic mapping with 
nuclear scanning, and intra-operative localization with a hand-
held gamma probe and subsequent removal of the sentinel lymph 
nodes for detailed pathologic evaluation. The technique and uti-
lization of SLNB has been well-established for the management 
of breast carcinoma (53) and melanoma (54), but the applica-
tion in OCSCC has not been clearly established. A prospective 
European study reported that the sensitivity of SLNB for the 
identification of cervical lymph node disease was 93% (55). A 
more recent prospective multi-institutional trial employed SLNB 
for 140 patients with T1 or T2 oral cavity cancers, and followed 
the procedure with completion selective neck dissection (56). 
The study reported a negative predictive value of 96% and a 
true-positive rate of 90.2%. Both trials suggested that the accu-
racy of SLNB was greater for oral tongue cancer than for other 
sites of the oral cavity, particularly the floor of mouth (55, 56).
  The pathologic assessment of the cervical lymph nodes is a 
crucial component of diagnostic and prognostic workup, and the 
presence of lymphatic disease weighs heavily on the treatment 
plan for the patient with OCSCC. The presence of multiple 
lymph nodes with metastatic disease significantly impacts dis-
ease stage (designated Stage IV) and the involvement of greater 
than 2 lymph nodes has been repeatedly identified as a risk fac-
tor that correlates with treatment failure (57, 58) in patients 
with HNSCC. The presence of extracapsular spread of lymph 
node disease has been well documented to correlate with poor 
prognosis (57-59), and was found in two large randomized trials 
to be an indication for the addition of cisplatin to adjuvant radi-
ation.
SURGICAL RECONSTRUCTION
A variety of reconstruction options exist for oral cavity defects 
after surgical resection, and methods of reconstruction range 
from healing from secondary intention or primary closure, to 
reconstruction with skin grafts, local or regional flaps, to micro-
vascular reconstruction with free-tissue transfer. A detailed dis-
cussion of these various options is beyond the scope of this re-
view, but microvascular free-tissue transfer has revolutionized 
our current management of locally advanced OCSCC and de-
serves more detailed mention here. 
  Reconstruction of the tongue has been significantly improved 
with the use of free tissue transfer. The radial forearm free flap 
was first used for oral reconstruction in the 1980’s (60), and 
since that time has become one of the primary reconstruction 
options for large partial glossectomy defects. These reconstruc-
tions are associated with improved deglutition and speech for 
patients after large tongue resections (61-63). The anterolateral 
thigh flap has more recently been advocated for tongue recon-
struction due to its similar versatility and decreased donor site 
morbidity (64, 65). Total glossectomy defects offer additional 
challenges. Total glossectomy is a particularly morbid procedure, 
and the aspiration risk associated with resection of the base of 
tongue may even necessitate total laryngectomy for functional 
rather than oncologic indications in some cases. For this reason, 
chemotherapy and radiation are often offered as primary treat-
ment, with surgery reserved for salvage in these situations. Total 
glossectomy can be considered without laryngectomy in both 
primary and salvage cases when the supraglottis is spared (66). 
Reconstruction of the total glossectomy deficit requires signifi-
cant tissue bulk for replacement, and this is most often accom-
plished with the rectus abdominus (67) or lattisimus dorsi free 
flap (68).
  Free microvascular reconstruction of the mandible after seg-
mental resection has become routine for these defects. The fibu-
lar free flap is the primary microvascular flap used for mandible 
reconstruction (64). Several other osteocutaneous flaps have 
been described for the potential reconstruction of the bony and 
soft tissue deficits after composite resection of cancer involving 
the mandible. These include the radial forearm osteocutaneous, 
scapula osteofasciocutaneous, and iliac crest osteomyocutane-
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struction of the mandible has greatly improved functional and 
cosmetic outcome in patients with this advanced disease (61, 69). 
  Large palatal and maxillary defects are repaired with free tis-
sue transfer, as well. Soft tissue free flaps can be used to elimi-
nate oronasal communication after a palatal defect is created 
(64, 70) . If there is significant loss of the anterior maxilla, a fib-
ular free flap can be fashioned to recreate the projection of the 
midface and anterior hard palate (64, 70, 71). For small- to mod-
erate-sized defects in the hard palate, obturation is an option for 
management of the oronasal communication after surgery. The 
costs and benefits of obturation versus free flap reconstruction 
have been analyzed (72, 73), but the ultimate decision is a mul-
tidisciplinary plan based on the defect, patient factors, and phy-
sician preference.
  The complex functional and cosmetic deficits that result from 
composite resection of OCSCC have significant impact on mor-
bidity and quality of life for patients with this disease. Free mi-
crovascular tissue reconstruction has greatly increased the ability 
of the head and neck surgeon to resect advanced local disease 
with adequate restoration of speech, deglutition, oral compe-
tence, and cosmesis.
RADIATION THERAPY
Radiation is not the primary treatment for OCSCC due to the 
significant morbidity that can result from high dose radiation to 
the oral cavity, particularly the risk of mandibular osteoradione-
crosis (33), as well as the the debilitating mucositis that can en-
sue. For patients with advanced local disease, or for those with 
multiple or extensive lymph node involvement, post-operative 
radiotherapy (PORT) has become the standard of care. No ran-
domized trials have been performed to compare surgery alone 
to surgery plus PORT for advanced OCSCC, but there is retro-
spective data that has shown that PORT improves local-regional 
control and survival in these patients (74-78). 
  PORT has become widely used for patients with stage III or 
IV OCSCC. Multivariate analyses have suggested that squamous 
cell cancer of the oral cavity is linked to a higher risk of local-
regional failure as compared to other sites of the head and neck 
(58, 79, 80). Advanced resectable local disease for which PORT 
is considered includes those with gross mandibular invasion, ex-
tension into the pterygoid musculature, or deep invasion of the 
tongue. High-risk features, such as perineural invasion, positive 
surgical margins, or poor differentiation have been associated 
with reduced local control and certainly justify the recommen-
dation of PORT, even if lymph node disease is not present (58, 
79). PORT has also become standard of care for patients with 
lymph node metastasis. PORT appears to improve local-regional 
control and survival for patients with two or more metastatic 
lymph nodes, and extracapsular spread of disease, all of which 
have been associated with poor outcomes (74-76). These factors 
certainly warrant the use of PORT and in the case of extracap-
sular spread, the addition of concomitant chemotherapy (10). It 
is unclear if patients with T1-2 local disease with N1 or N2a dis-
ease benefit from the addition of PORT to local resection and 
neck dissection, but retrospective analyses have suggested there 
may be a benefit for PORT in this subgroup of patients (44, 77). 
  During the last decade, the toxicity associated with radiation 
to the oral cavity and neck has been improved with the advent 
of intensity-modulated radiation therapy (IMRT). IMRT allows 
the delivery of high-dose radiation to specific sites of the head 
and neck, with lower dose delivered to adjacent regions that are 
uninvolved or at lower risk of disease. The radiation dose to im-
portant radiosensitive structures, such as the salivary glands, 
aerodigestive mucosa, spinal cord, and brachial plexus, can be 
relatively reduced with this method (81, 82). Though few direct 
comparisons exist, IMRT appears to have equivalent, if not im-
proved efficacy in controlling local-regional disease as compared 
to conventional 3-dimensional conformal techniques (82-86). 
IMRT appears to have a decreased rate of toxicity compared to 
conventional radiotherapy, including improved rates of mucosi-
tis, xerostomia, and dysphagia (82, 87) 
CHEMOTHERAPY
Since the establishment of combined surgery and radiation for 
the treatment of advanced OCSCC, several studies have identi-
fied factors that appear to correlate with poor outcome despite 
this treatment (57, 58, 79). Perineural invasion, oral cavity dis-
ease site, positive surgical margins, multiple positive lymph 
nodes, and extracapsular spread of lymphatic disease have been 
identified as unfavorable factors. During the last decade, studies 
have evaluated the utility of triple modality therapy, adding con-
current cisplatin to postoperative radiotherapy (88). In 2004, 
two landmark randomized multi-institutional studies, RTOG 
9501 and EORTC 22931, demonstrated the advantages of the 
addition of platinum-based chemotherapy to postoperative radi-
ation in patients with high-risk, resectable head and neck squa-
mous cell carcinoma (9, 11). Both studies showed improvement 
in local-regional control and disease-free survival with concur-
rent cisplatin-PORT, and the EORTC study reported an improve-
ment in overall survival. The RTOG reported increased toxicity 
and four mortalities from the intensified treatment, whereas the 
EORTC reported less toxicity and did not have treatment-relat-
ed deaths (9, 11). Combined review of the two studies clearly 
defined patients with extracapsular spread of disease and posi-
tive surgical margins as a subgroup that derived significant ben-
efit from escalated treatment (10), and these are now definitive 
indications for the addition of concurrent cisplatin to PORT. 
  Another advancement in the management of OCSCC was the 
development and utilization of cetuximab, the humanized mono-
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tor (EGFR). In 2006, a multi-institutional, randomized phase III 
trial compared radiotherapy versus radiotherapy plus cetuximab 
for the treatment of patients with stage III or IV oropharynx, 
hypopharynx, or larynx squamous cell carcinoma, and showed 
a significant improvement in overall and disease-free survival 
for patients treated with cetuximab (89). Though cetuximab has 
been proven to be an effective agent for concurrent chemoradia-
tion during the primary treatment of disease, a role for post-op-
erative chemoradiation using cetuximab has not been fully es-
tablished. For some cases of high-risk OCSCC, PORT plus ce-
tuximab may prove to be a useful option with less toxic effects 
than cisplatin, but further evaluation is necessary.
  More recent studies have been conducted to attempt to im-
prove upon the control rates for high-risk HNSCC achieved in 
RTOG 9501 and EROTC 22931. RTOG 0024 has examined the 
use of early post-operative paclitaxel followed by a chemoradia-
tion regimen that included both cisplatin and paclitaxel (90). Of 
the 70 patients enrolled in this phase II study, seven experienced 
grade 4 non-hematologic toxicity, one experienced grade 4 late 
toxicity, and one patient died of myocardial ischemia. After ad-
justment for multiple prognostic variables, this study reported 
improved local-regional control, disease-free survival, and over-
all survival as compared to RTOG 9501. A second study, RTOG 
0234, examining the tolerability and efficacy of the addition of 
cetuximab to post-operative chemoradiation, has recently com-
pleted. The two arms of this study compared concurrent PORT 
and docetaxel plus cetuximab versus concurrent PORT and cis-
platin plus cetuximab. Preliminary analysis suggests these regi-
mens are tolerated at an acceptable rate, and there appears to be 
improvement in disease-free survival and perhaps distant con-
trol with the docetaxel arm (unpublished data). 
  As the risk factors for treatment failure become more clear, 
and the treatments that can be offered to these patients im-
proves, there is a growing need to find ways to intensify treat-
ment while limiting the toxic effects. Although studies such as 
those described above offer patients with high-risk OCSCC an 
improved chance at cure, a large portion of patients continue to 
fail multi-modality treatment. 
SALVAGE THERAPY FOR RECURRENT DISEASE
Local and/or regional recurrence can be expected to occur with-
in 5 years in roughly 50-60% of patients with advanced resect-
able HNSCC treated with combined modality treatment (9, 11). 
The outcomes of salvage surgery can be favorable in properly 
selected patients, and the surgeon and patient must weigh the 
costs and benefits of surgical resection when faced with recur-
rent disease (91). A recent study reported a median survival of 
44.8 months after salvage surgery for patients undergoing resec-
tion and free-flap reconstruction for oral cavity recurrence (92). 
Neck recurrence and a short time to relapse have been associat-
ed with a less favorable outcome (92-94).
  Surgical salvage offers the best chance at cure for patients 
with recurrent OCSCC (93, 95). Reirradiation is a modality that 
has gained increased use in the recurrent setting, and there are 
several techniques in which this can be employed. If surgery is 
not an option, either because 1) recurrent disease is unresect-
able; 2) surgery would lead to unacceptable morbidity; 3)sur-
gery is unsafe due to the patient’s medical condition, or 4) pa-
tient refusal, then reirradiation with or without cisplatin-based 
chemotherapy is the best option (96). Reirradiation can be of-
fered as external beam therapy, brachytherapy, and as an adju-
vant in the post-operative setting when surgery is feasible (97). 
There is a high degree of grade III and IV toxicity associated with 
reirradiation, and when combined with salvage surgery the risks 
of osteoradionecrosis, tissue necrosis, and the development of 
orocutaneous and pharyngocutaneous fistulas are increased (96-
98). Reirradiation with concurrent cisplatin treatment is increas-
ingly being utilized, and may be a reason for decreased func-
tional outcomes, namely tracheotomy and gastrostomy tube de-
pendence, reported in patients treated with reirradiation during 
the last decade (96).
  When patients present with recurrent disease after initial 
treatment for oral cavity cancer, it is more important to ask 
‘what should be done?’ than to ask ‘what can be done?’ As stat-
ed above, surgical salvage is the best chance at cure, but surgical 
resection of recurrent disease carries a high morbidity rate, es-
pecially in the post-radiation setting when advanced disease is 
present. Patients with early stage recurrence can expect a rea-
sonable chance of being disease-free at two years, however stage 
4 recurrence and/or recurrence in the neck carry a median sur-
vival of only 9 months (91). Overall, patients with recurrence in 
the oral cavity appear to have a worse prognosis and a worse 
quality of life as compared to those with recurrence of laryngeal 
cancer, although these rates are highly dependent on the stage 
of recurrent disease (91). When faced with advanced recurrent 
disease, options other than curative treatment should be consid-
ered. Enrollment in a phase I study, palliative treatment includ-
ing chemotherapy, radiation, or a combination, or perhaps best 
supportive care in a hospice setting all must be considered when 
determining the best options to ensure optimal quality of life 
for the patient suffering with recurrent OCSCC. Treatment of re-
current disease carries a high degree of morbidity, and when the 
chance at cure is minimal, then every effort must be made to re-
lieve the patient’s pain and anxiety. Though hospice care appears 
to significantly improve these factors for patients with unresect-
able HNSCC (99), limited data analyzing quality of life in this 
patient group (100) make it difficult to determine which treat-
ment options are best for patients suffering with advanced re-
current OCSCC. The optimal management strategy for patients 
with incurable OCSCC is an area which needs improvement 
and further investigation. Ow TJ et al.: Treatment of Advanced Oral Cavity Cancer    7
FUTURE ADVANCES IN OCSCC
The treatment of OCSCC continues to evolve as new treatments 
and strategies are developed and studied. One ongoing challenge 
is the management of patients with extensive tongue cancer. 
Outcomes of total glossectomy have improved greatly with the 
use of microvascular reconstruction (66), but continues to pose 
significant functional challenges for the patient faced with this 
procedure. With improved chemotherapeutic agents and techni-
cal advances in the delivery of radiotherapy, the role for chemo-
radiation for advanced oral cavity cancer is being revisited. A re-
cent study reported 6.5% 5-year progression-free survival, and 
good functional outcome (101) using a chemoradiation strategy 
for advanced oral cavity cancer. Nine of 49 patients in this study 
developed oseteoradionecrosis, and these rates must be further 
compared to those that develop after surgical resection and 
modern PORT techniques. 
  Strategies for managing cancer in other sites of the body are 
becoming increasingly individualized to the molecular profile of 
a patient’s tumor. Treatment options that incorporate a molecu-
lar marker into the management of OCSCC have yet to be de-
veloped, but genetic alterations in p53 (102, 103) and EGFR 
(104) have been associated with outcome and response to treat-
ment in HNSCC. Molecular therapy in the treatment of HNSCC 
has been largely focused on inhibition of EGFR, and several 
agents are under evaluation (105). The role for these agents as 
an adjuvant in post-operative concurrent chemoradiotherapy 
are being established. 
CONCLUSION
Treatment for advanced OCSCC requires a multi-disciplinary 
approach which combines surgery with radiotherapy and cispla-
tin-based chemoradiotherapy for high-risk cases. Advances in 
surgical resection and reconstruction, the delivery of radiation, 
and in chemotherapeutic strategies have improved the manage-
ment of patients with advanced OCSCC, but the high rate of 
treatment failure and morbidity of treatment must be improved   
by future advances in the management of this disease. 
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